Abcam completes acquisition of life science research tool distributor

(Alliance News) - Abcam PLC on Wednesday completed the acquisition of BioVision Inc from Boai NKY ...

Alliance News 27 October, 2021 | 9:15AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Abcam PLC on Wednesday completed the acquisition of BioVision Inc from Boai NKY Medical Holdings Ltd for USD340 million.

Cambridge, England-based Abcam is a life science research firm. BioVision is a distributor of life science research tools to biopharma, diagnostic and academic customers.

The acquisition accelerates Abcam's strategic focus in the market for products in the complementary biochemical and cell-based assay market, the company said. It will additionally create value through portfolio expansion and leverage Abcam's global channels to market, it added.

"We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Bringing BioVision's product portfolio and capabilities into Abcam, particularly its strengths in biochemical and cell-based assays, will further enhance our ability to support life scientists globally," Abcam Chief Executive Alan Hirzel said.

In August, Abcam said the acquisition is expected to be accretive to adjusted earnings per share from the first full year of ownership.

Abcam shares were up 0.6% to 1,655.00 pence each in London on Wednesday morning.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Abcam PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures